Predictive Model for the Risk of Cytokine Release Syndrome with Glofitamab Treatment for Diffuse Large B-cell Lymphoma

Overview

Journal Blood Adv

Specialty Hematology

Date 2024 May 14

PMID 38743882

Authors

Giuseppe Gritti

Anton Belousov

James Relf

Mark Dixon

Maneesh Tandon

Krishna Komanduri

Affiliations

Soon will be listed here.

Citing Articles

Comprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies.

Bangolo A, Amoozgar B, Mansour C, Zhang L, Gill S, Ip A Cancers (Basel). 2025; 17(2).

PMID: 39858064 PMC: 11764151. DOI: 10.3390/cancers17020282.

Clinical Pharmacology of Cytokine Release Syndrome with T-Cell-Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies.

Radtke K, Bender B, Li Z, Turner D, Roy S, Belousov A Clin Cancer Res. 2024; 31(2):245-257.

PMID: 39556515 PMC: 11739781. DOI: 10.1158/1078-0432.CCR-24-2247.

References

Falconer N, Barras M, Cottrell N . Systematic review of predictive risk models for adverse drug events in hospitalized patients. Br J Clin Pharmacol. 2018; 84(5):846-864. PMC: 5903258. DOI: 10.1111/bcp.13514. View

Lussana F, Gritti G, Rambaldi A . Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell-Redirected Bispecific Antibodies. J Clin Oncol. 2021; 39(5):444-455. PMC: 8078487. DOI: 10.1200/JCO.20.01564. View

Cosenza M, Sacchi S, Pozzi S . Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and Treatment. Int J Mol Sci. 2021; 22(14). PMC: 8305850. DOI: 10.3390/ijms22147652. View

Morris E, Neelapu S, Giavridis T, Sadelain M . Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2021; 22(2):85-96. PMC: 8127450. DOI: 10.1038/s41577-021-00547-6. View

Osterman C, Sanoff H, Wood W, Fasold M, Lafata J . Predictive Modeling for Adverse Events and Risk Stratification Programs for People Receiving Cancer Treatment. JCO Oncol Pract. 2021; 18(2):127-136. PMC: 9213197. DOI: 10.1200/OP.21.00198. View

Lee D, Santomasso B, Locke F, Ghobadi A, Turtle C, Brudno J . ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2018; 25(4):625-638. DOI: 10.1016/j.bbmt.2018.12.758. View

Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner F, Sureda A . Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. J Clin Oncol. 2021; 39(18):1959-1970. PMC: 8210975. DOI: 10.1200/JCO.20.03175. View

Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W . International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol. 2017; 28(7):1436-1447. PMC: 5834038. DOI: 10.1093/annonc/mdx097. View

Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S . CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies. Clin Cancer Res. 2018; 24(19):4785-4797. DOI: 10.1158/1078-0432.CCR-18-0455. View

10.

Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M . Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010; 28(14):2373-80. DOI: 10.1200/JCO.2009.26.2493. View

11.

Crombie J, Graff T, Falchi L, Karimi Y, Bannerji R, Nastoupil L . Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Blood. 2024; 143(16):1565-1575. DOI: 10.1182/blood.2023022432. View

12.

Yan Z, Zhang H, Cao J, Zhang C, Liu H, Huang H . Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment. Front Immunol. 2021; 12:611366. PMC: 7940756. DOI: 10.3389/fimmu.2021.611366. View